Lupin, Yoshindo spin out YL Biologics to develop biosimilars in Japan
By Cornelia Zou
Monday, April 28, 2014
HONG KONG – Indian pharmaceutical company Lupin Ltd. (BSE:500257, NSE:LUPIN) plans to launch a new company dedicated to biosimilars in Japan with its Japanese partner, Toyama-based pharmaceutical Yoshindo Inc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.